Abstract
Present work is aimed to develop a simple, sensitive, robust and reliable HPLC method for routine quality control of epirubicin (EPI) in bulk drug, marketed injections and polymeric nanoparticles. Separation was carried out by C18 column. Isocratic elution was carried out using mobile phase A: 0.16% o-phosphoric acid solution, B: acetonitrile and methanol mixture (80:20, v/v) in the ratio of 60:40 (A: B) while the flow rate was maintained at 1mL/min. Analyses were performed at 233.5 nm using PDA detector. Excellent linear relationship was observed between peak-area versus drug concentration in the range of 1.0‑100.0 μg/mL (r2 , 0.999). Developed method was found to be sensitive (Limits of detection and quantification were found to be ~8 ng/mL and ~25 ng/mL, respectively), precise (RSD <1.0%, for repeatability and <2.0% for intermediate precision, within acceptable ranges of precision), accurate (recovery in different dosage form, 94.65 -100.26%, within acceptable range, 80-120%), specific and robust (% RSD <2, for system suitability parameters). Stress-induced degradation studies demonstrated that method can suitability be applied in the presence of degradants. Developed method has been successfully applied for the determination of entrapment efficiency, drug loading, in vitro release profile, in vitro permeation studies as well as stability assessment of polymeric nanoparticles.
Highlights
Epirubicin (10-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,8,11-trihydroxy-8-(2hydroxy acetyl)1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione) is an anthracycline anticancer agent which is used for the treatment of node positive breast cancer, ovarian cancer, gastric cancer, lung cancer and lymphomas (Neil, 2006)
Epirubicin is obtained by chemical transformation of a substance produced by certain strains of Streptomyces peucetius (Neil, 2006)
As the epirubicin hydrochloride is an ionizable compound best peak was expected at lower pH pH adjusted with phosphoric acid which resulted in best peak with good symmetry and high resolution
Summary
Epirubicin (10-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,8,11-trihydroxy-8-(2hydroxy acetyl)1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione) is an anthracycline anticancer agent which is used for the treatment of node positive breast cancer, ovarian cancer, gastric cancer, lung cancer and lymphomas (Neil, 2006). Epirubicin is obtained by chemical transformation of a substance produced by certain strains of Streptomyces peucetius (Neil, 2006). It acts by forming a complex with DNA by intercalation into nucleotide base pairs hindering DNA and RNA synthesis (Omrod et al, 1999). It is favoured over doxorubicin as it is found to be less.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
